Search company, investor...


Founded Year



Acquired | Acquired

Total Raised


About Abgenix

Abgenix aims to deliver fully human monoclonal antibodies for a range of disease targets, several of which are currently in clinical trials. The company leverages its XenoMouse technology platform to support product development, while offering the platform to its strategic partners and licensing customers.

Headquarters Location

6701 Kaiser Drive

Fremont, California, 94555,

United States


Missing: Abgenix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Abgenix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Abgenix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Abgenix is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Abgenix Patents

Abgenix has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics




Monoclonal antibodies, Clusters of differentiation, Immunology, Immune system, Experimental cancer drugs


Application Date


Grant Date



Related Topics

Monoclonal antibodies, Clusters of differentiation, Immunology, Immune system, Experimental cancer drugs



Latest Abgenix News

Open Monoclonal Technology Announces OmniAb Alliance With Amgen

Jun 14, 2015

Amgen licenses AMG 714 to start-up Celimmune Dr. Roland Buelow, OMT founder and CEO, said, “Amgen was an early protein therapeutics leader and became one of a few companies with transgenic mouse platforms for human antibody discovery in 2005 when they acquired Abgenix and its XenoMouse®. With the license from OMT, Amgen further builds on this capability as it gains access to complementary platforms for development of fully human, mono- and bispecific antibodies without any target restrictions.” About Open Monoclonal Technology, Inc. Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for the generation of human therapeutic antibodies, naturally optimized human antibodies®, and the only company in the world with four transgenic animal platforms, jointly known as OmniAb™. OmniRat® is the industry’s first human monoclonal antibody technology based on rats. It has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as wild-type animals make rat antibodies. OmniMouse® is a transgenic mouse that complements OmniRat and expands epitope coverage. OmniFlic™ is an engineered rat with a fixed light chain for development of bispecific, fully human antibodies. UniRat™ is the first transgenic rat generating fully human heavy chain-only antibodies and nanobodies for polyspecific applications. All four OmniAb™ platforms deliver human antibodies with high affinity, specificity, expression, solubility and stability. They use patented technology, have broad freedom to operate and are available worldwide for all targets and indications. Current partners include Amgen, Caltech, Celgene, Chugai, Genmab, Genentech, HanAll, Janssen, Merck KGaA, Pfizer, Roche, Symphogen, University of Nottingham and several undisclosed biotech and pharmaceutical companies. Animal hosting and OmniAb antibody discovery services are available via Antibody Solutions, Panoply Bio and Sage Labs in the US, Aldevron and Taconic Biosciences in Europe, and WuXi AppTec in China. For more information, please visit . View source version on Open Monoclonal Technology, Inc.

Abgenix Frequently Asked Questions (FAQ)

  • When was Abgenix founded?

    Abgenix was founded in 1996.

  • Where is Abgenix's headquarters?

    Abgenix's headquarters is located at 6701 Kaiser Drive, Fremont.

  • What is Abgenix's latest funding round?

    Abgenix's latest funding round is Acquired.

  • How much did Abgenix raise?

    Abgenix raised a total of $246.64M.

  • Who are the investors of Abgenix?

    Investors of Abgenix include Amgen, HBM Healthcare Investments, HBM Partners, RS Investments, TAIB Bank B.S.C. and 27 more.

  • Who are Abgenix's competitors?

    Competitors of Abgenix include Cevec Pharmaceuticals, Constellation Pharmaceuticals, Ambrx, ImmunoReagents, Merus and 11 more.

Compare Abgenix to Competitors

ImmunoReagents Logo

ImmunoReagents is a cGMP manufacturing facility for antibodies used in the In Vitro Diagnostic Industry, which specializes in polyclonal antibodies to human proteins and secondary antibodies.


ApoLife has developed platform yeast expression technologies for accelerated development of therapeutic antibodies (glycosylated and aglycosylated), antibody fragments, fusion proteins and antibodies and subunit vaccines through its Twin Cassette yeast system. ApoLife employs Bakers yeast (S.cerevisiae) which has been used for manufacturing several FDA approved therapeutic products thus giving ApoLife a competitive regulatory advantage over companies using other yeast systems. ApoLife's platform has the capability to make fully functional secreted antibodies and has potential to improve antibody potency. The technology has the capability to accelerate the process of identifying and selecting antibodies for target antigens, reducing the cost and development time by up to 50% of the current process.ApoLife uses its technology to develop anticancer antibodies and immunotoxins with collaborating partners.As a licensing partner, ApoLife has vectors, yeast strains, and production process available for antibody and biogeneric product development.


IMED AB develops human monoclonal antibodies (MABs) that can induce or block natural cell death (apoptosis). There are many medical uses for these antibodies including HIV, cancer and transplantation. The company intends to license its products to large pharmaceutical companies.


Grand River Aseptic Pharmaceutical Packaging is a pharmaceutical contract manufacturing organization (CMO) supporting the rapid development of new biomedicines to the clinical stage in the State of Michigan. Grand River APP is the result of an alliance between Van Andel Institute ( and Grand Valley State University, and is operating as a non-profit, state- and federally funded corporation. Grand River APP's first aims to assure that therapeutics are properly distributed into dosage forms for all-important Phase I and Phase II human clinical trials. This process, Fill/Finish and Lyophilization, will be offered broadly to academic, nonprofit, and for-profit organizations in Michigan and across North America for liquid-based drug candidates that require vialing in an FDA-regulated aseptic clean room environment. Typical products envisioned for Grand River APP services include small molecule drugs, peptides, monoclonal antibodies, therapeutic proteins and nano-medicines. As a consequence, however, Grand River APP cannot process cytotoxic/genotoxic or virally-based candidates (e.g. viral vaccines).

Oxford BioTherapeutics Logo
Oxford BioTherapeutics

Oxford BioTherapeutics is an international, clinical-stage biotechnology company focused on developing antibody-based therapies to treat cancer. Combining immuno-oncology, antibody-drug conjugates, and fully human monoclonal antibody approaches against novel human tumor cell membrane-derived checkpoint targets identified using its unique target selection and validation platform, the Company has gathered compelling in vivo evidence of the potency of its broad pipeline.


PhenoTech, Inc. was founded in 2003 and funded by BioAdvance in March 2004. PhenoTech was created to develop University of Pennsylvania technology for the discovery, development and commercialization of monoclonal antibodies (mAbs) to be used in blood diagnostic and blood therapeutic applications. The company is in the process of winding down operations.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.